Skip to main navigation Skip to main content

CMH : Clinical and Molecular Hepatology

OPEN ACCESS
ABOUT
BROWSE ARTICLES
FOR CONTRIBUTORS

Page Path

2
results for

"Ji Hyun Kim"

Article category

Keywords

Publication year

"Ji Hyun Kim"

Original Articles
Reappraisal of sepsis-3 and CLIF-SOFA as predictors of mortality in patients with cirrhosis and infection presenting to the emergency department: A multicenter study
Ji Hyun Kim, Baek Gyu Jun, Minjong Lee, Hye Ah Lee, Tae Suk Kim, Jeong Won Heo, Da Hye Moon, Seong Hee Kang, Ki Tae Suk, Moon Young Kim, Young Don Kim, Gab Jin Cheon, Soon Koo Baik, Dong Joon Kim, Dae Hee Choi
Clin Mol Hepatol 2022;28(3):540-552.
Published online May 6, 2022
DOI: https://doi.org/10.3350/cmh.2021.0169
Background/Aims
Sepsis-3 criteria and quick Sequential Organ Failure Assessment (qSOFA) have been advocated to be used in defining sepsis in the general population. We aimed to compare the Sepsis-3 criteria and Chronic Liver Failure-SOFA (CLIF-SOFA) scores as predictors of in-hospital mortality in cirrhotic patients admitted to the emergency department (ED) for infections.
Methods
A total of 1,622 cirrhosis patients admitted at the ED for infections were assessed retrospectively. We analyzed their demographic, laboratory, and microbiological data upon diagnosis of the infection. The primary endpoint was inhospital mortality rate. The predictive performances of baseline CLIF-SOFA, Sepsis-3, and qSOFA scores for in-hospital mortality were evaluated.
Results
The CLIF-SOFA score proved to be significantly better in predicting in-hospital mortality (area under the receiver operating characteristic curve [AUROC], 0.80; 95% confidence interval [CI], 0.78–0.82) than the Sepsis-3 (AUROC, 0.75; 95% CI, 0.72–0.77, P<0.001) and qSOFA (AUROC, 0.67; 95% CI, 0.64–0.70; P<0.001) score. The CLIF-SOFA, CLIF-C-AD scores, Sepsis-3 criteria, septic shock, and qSOFA positivity were significantly associated with in-hospital mortality (adjusted hazard ratio [aHR], 1.24; 95% CI, 1.19–1.28; aHR, 1.13; 95% CI, 1.09–1.17; aHR, 1.19; 95% CI, 1.15–1.24; aHR, 1.88; 95% CI, 1.42–2.48; aHR, 2.06; 95% CI, 1.55–2.72; respectively; all P<0.001). For CLIF-SOFA scores ≥6, in-hospital mortality was >10%; this is the cutoff point for the definition of sepsis.
Conclusions
Among cirrhosis patients presenting with infections at the ED, CLIF-SOFA scores showed a better predictive performance for mortality than both Sepsis-3 criteria and qSOFA scores, and can be a useful tool of risk stratification in cirrhotic patients requiring timely intervention for infection.

Citations

Citations to this article as recorded by  Crossref logo
  • Interpretable model for early prediction of 28-day mortality in patients with cirrhosis and sepsis: a multi-cohort ICU study
    Xin Xu, Jingjing Li, Haijing Yu, Jiaquan Huang
    BMC Gastroenterology.2026;[Epub]     CrossRef
  • A Serum DLL1 and CRP dual-marker model for bacterial infection detection in patients with decompensated cirrhosis: A dual-cohort diagnostic study
    Juanjun Huang, Luhu Yu, Debin Zeng, Yulin Wang, Zhi Wang, Jian Chen, Wei Zhu
    Science Progress.2025;[Epub]     CrossRef
  • Correlation between systemic inflammatory response syndrome and prognosis of patients with cirrhosis and hepatic encephalopathy
    Kaiyue Zhang, Ziqun Qu, Rongyu Tang, Hongliang Dong, Jing Fan, Wei Ye
    BMC Gastroenterology.2025;[Epub]     CrossRef
  • Management of patients with cirrhosis in the emergency department: Implications for hospitalization outcomes
    Sandeep Sikerwar, Sohrab Zand, Peter Steel, Arun Jesudian
    Liver Transplantation.2024; 30(1): 94.     CrossRef
  • Current Status of Prognostic Evaluation Model and Treatment of Acute-on-Chronic Liver Failure
    念 刘
    Advances in Clinical Medicine.2024; 14(04): 2500.     CrossRef
  • Prevalence and predictors of multidrug-resistant bacteremia in liver cirrhosis
    Aryoung Kim, Byeong Geun Song, Wonseok Kang, Dong Hyun Sinn, Geum-Youn Gwak, Yong-Han Paik, Moon Seok Choi, Joon Hyeok Lee, Myung Ji Goh
    The Korean Journal of Internal Medicine.2024; 39(3): 448.     CrossRef
  • Dynamic analysis of acute deterioration in chronic liver disease patients using modified quick sequential organ failure assessment
    Do Seon Song, Hee Yeon Kim, Young Kul Jung, Tae Hyung Kim, Hyung Joon Yim, Eileen L Yoon, Ki Tae Suk, Jeong-ju Yoo, Sang Gyune Kim, Moon Young Kim, Young Chang, Soung Won Jeong, Jae Young Jang, Sung-Eun Kim, Jung-Hee Kim, Jung Gil Park, Won Kim, Jin Mo Ya
    Clinical and Molecular Hepatology.2024; 30(3): 388.     CrossRef
  • Correspondence to editorial on “Dynamic analysis of acute deterioration in chronic liver disease patients using modified quick sequential organ failure assessment”
    Do Seon Song, Dong Joon Kim
    Clinical and Molecular Hepatology.2024; 30(4): 1012.     CrossRef
  • Cirrhosis Management in the Intensive Care Unit
    Thomas N. Smith, Alice Gallo de Moraes, Douglas A. Simonetto
    Seminars in Liver Disease.2023; 43(01): 117.     CrossRef
  • 8,624 View
  • 146 Download
  • 7 Web of Science
  • Crossref
Durability of a sustained virological response in chronic hepatitis C patients treated with pegylated interferon alfa and ribavirin
Sang Bun Choi, Youn Jae Lee, Jae Ik Lee, Young Jin Song, Byoung Jin Choi, Jong Han Kim, Eun Uk Jung, Sung Jae Park, Sang Heon Lee, Ji Hyun Kim, Jung Sik Choi, Sam Ryong Jee, Sang Yong Seol
Korean J Hepatol 2011;17(3):183-188.
Published online September 30, 2011
DOI: https://doi.org/10.3350/kjhep.2011.17.3.183
Background/Aims

The reappearance rates of hepatitis C virus (HCV) RNA after a sustained virological response (SVR) have been reported to be 1-2%. We investigated the reappearance rate of HCV RNA after SVR in chronic hepatitis C (CHC) patients treated with pegylated interferon (PEG-IFN) and ribavirin.

Methods

In total, 292 CHC patients who achieved an SVR after PEG-IFN and ribavirin treatment were included. They were treated with subcutaneous injections of either PEG-IFN-α 2a or 2b plus ribavirin orally. Liver function tests and qualitative HCV RNA assays were performed every 6 months during the follow-up period after an SVR.

Results

Among the 292 patients, 224 (genotype 1, 92; genotype non-1, 132) were followed up for more than 6 months after SVR. These 224 patients were aged 48.1±11.5 years (mean±SD), and 129 of them were male. The median follow-up duration was 18 months (range 6-60 months). The reappearance rate of HCV RNA during follow-up was 0%. Two patients who achieved an SVR developed hepatocellular carcinoma during the follow-up period.

Conclusions

An SVR was maintained in all CHC patients treated with PEG-IFN plus ribavirin during a median follow-up of 18 months. However, a screening test for hepatocellular carcinoma is needed for patients with an SVR.

Citations

Citations to this article as recorded by  Crossref logo
  • Risk of Late Relapse or Reinfection With Hepatitis C Virus After Achieving a Sustained Virological Response: A Systematic Review and Meta-analysis
    Bryony Simmons, Jawaad Saleem, Andrew Hill, Richard D. Riley, Graham S. Cooke
    Clinical Infectious Diseases.2016; 62(6): 683.     CrossRef
  • Long-term maintenance of sustained virological response in liver transplant recipients treated for recurrent hepatitis C
    Francesca Romana Ponziani, Raffaella Viganò, Rosa Maria Iemmolo, Maria Francesca Donato, Maria Rendina, Pierluigi Toniutto, Luisa Pasulo, Maria Cristina Morelli, Patrizia Burra, Lucia Miglioresi, Manuela Merli, Daniele Di Paolo, Stefano Fagiuoli, Antonio
    Digestive and Liver Disease.2014; 46(5): 440.     CrossRef
  • Durability of antiviral therapy for chronic hepatitis C after achieving sustained virological response
    Jeong Heo
    The Korean Journal of Hepatology.2011; 17(3): 180.     CrossRef
  • 9,506 View
  • 39 Download
  • Crossref